Novartis/Fougera Pharma

Target: Fougera Pharma
Buyer: Novartis ($NVS)
Price: $1.5 billion
Closed: July 23, 2012

Novartis wanted more skin in the generics game, and it got it in specialty dermatology drugmaker Fougera Pharma. By adding Fougera's drugs to the portfolio held by Sandoz, the Swiss company's generics unit, it suddenly was the leader in dermatology knockoffs. The deal also promised to add some revenue as Novartis' top drug, Diovan, headed for generic competition irrelevance.

Novartis has plans to expand the business to take advantage of the growing number of branded dermatology drugs going off patent. It also sees opportunities to build it internationally. As Sandoz CEO Jeff George said at the time, "We see great potential to take a business that's a U.S. business and take it globally."

Novartis/Fougera Pharma
Read more on

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.